SEC Filing Summary: SIGA Technologies Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 21, 2004, discloses unaudited pro forma financial information for SIGA Technologies, Inc. The report provides a retrospective view of the company's operations for the year ended December 31, 2003, assuming the acquisition of substantially all assets of Plexus Vaccine Inc. ("Plexus") occurred on January 1, 2003. The actual asset purchase agreement was consummated on May 23, 2003.
Key Financial Metrics (Pro Forma Year Ended Dec 31, 2003)
| Metric | Pro Forma Combined |
|---|---|
| Total Revenues | $826,525 |
| Total Operating Expenses | $7,422,858 |
| Operating Loss | $(6,596,333) |
| Net Loss | $(7,527,206) |
| Net Loss Per Share (Basic & Diluted) | $(0.46) |
| Weighted Average Shares Outstanding | 16,481,110 |
Note: The filing does not provide specific data on cash flow, debt levels, or liquidity ratios for the pro forma period.
Material Changes and Transaction Details
The primary material change reflected in this filing is the consolidation of Plexus Vaccine Inc. into SIGA's financial results. Key transaction details include:
- Consideration: SIGA issued 1,950,000 shares of common stock and 190,950 options/warrants (exercise price $1.62) to acquire Plexus assets.
- Purchase Price Allocation: The preliminary purchase price of approximately $4,070,903 was allocated as follows:
- Acquired Technology: $2,191,000
- Contracts and Grants: $741,000
- Covenant Not to Compete: $707,000
- Goodwill: $898,334
- Net Liabilities Assumed: $(466,431)
- Pro Forma Adjustments: The combined results include amortization expenses for the covenant not to compete and acquired technology/contracts, as well as an increase in share count.
Outlook, Risks, and Management Commentary
Management explicitly states that the unaudited pro forma information is for illustrative purposes only. It is not necessarily indicative of operating results that would have been achieved if the transaction occurred on January 1, 2003, nor does it predict future results. The pro forma data does not account for potential cost savings or incremental costs resulting from the integration of SIGA and Plexus operations.
The filing details the valuation methodologies used for intangible assets, including a relief-from-royalty approach for technology (3.0% royalty rate, 28.5% discount rate) and an excess earnings methodology for contracts (26.0% discount rate).
Investor Verification Checklist
- Verify the actual integration costs and synergies realized post-acquisition, as these are excluded from the pro forma data.
- Confirm the status and commercial viability of the acquired technology (one patent, two applications, six pending patents).
- Review the actual cash flow and liquidity position of the combined entity, as this filing focuses on pro forma operations rather than cash balances.
- Monitor the amortization schedule for the acquired intangible assets ($3.64 million total) and its impact on future net losses.